It can help your body adjust to the medication while minimizing the side effects. The semaglutide dosing chart below shows the dosing schedule for Wegovy (for weight loss) and Ozempic (for type 2 ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...